---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-274235"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:19:33.235918+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences Q3 net loss $9.2M; cash $232.6M; positive Phase 1b data for ABI-5366

## Summary
- Net loss of $9.2M ($0.72 per share) vs $9.6M loss in Q3 2024; revenue from Gilead collaboration $10.8M.
- Cash, cash equivalents and marketable securities $232.6M as of Sep 30, 2025; projected to fund operations into late 2027.
- Raised $175M gross proceeds from equity financing with institutional investors in August 2025.
- Positive Phase 1b interim data for ABI-5366: significant reductions in HSV-2 shedding and genital lesion rates in recurrent genital herpes.
- Phase 1a interim data for ABI-6250 supports progression to Phase 2; additional HSV data (ABI-5366, ABI-1179) expected by year-end.

## SEC filing metadata
- accession: 0001193125-25-274235
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000119312525274235/0001193125-25-274235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000119312525274235/asmb-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-274235
- JSON: https://secwatch.observer/filing/0001193125-25-274235.json
- Plain text: https://secwatch.observer/filing/0001193125-25-274235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.